OncoMatch/Clinical Trials/NCT07085572
Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer
Is NCT07085572 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cemiplimab for adrenal cortical carcinoma.
Treatment: Cemiplimab — This clinical trial is a single-arm, non-randomized, prospective phase II study. The study aims to evaluate if the maintenance immunotherapy with cemiplimab in patients with AdrenoCortical Carcinoma (ACC), who obtained disease response or stabilization after first-line chemotherapy, may delay/prevent disease progression. The study will be conducted at ASST Spedali Civili Hospital, Brescia - Italy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EDP-M induction therapy — first line
Previous induction therapy with EDP-M followed by cytoreductive surgery if indicated
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor
Cannot have received: allogeneic stem cell transplantation
Prior allogeneic stem cell transplantation
Cannot have received: autologous stem cell transplantation
autologous stem cell transplantation
Lab requirements
Blood counts
Hemoglobin >9.0 g/dL; ANC >1.5 x 10^9/L; Platelet count >75 x 10^9/L
Kidney function
Serum creatinine <1.5 ULN or estimated CrCl >30 mL/min
Liver function
Total bilirubin <1.5 x ULN; AST and ALT both <3 x ULN; ALP <2.5 x ULN; For patients with Gilbert's syndrome, total bilirubin ≤3x ULN
Adequate organ and bone marrow function documented by: Hemoglobin >9.0 g/dL; ANC >1.5 x 10^9/L; Platelet count >75 x 10^9/L; Serum creatinine <1.5 ULN or estimated CrCl >30 mL/min; Adequate hepatic function: Total bilirubin <1.5 x ULN; AST and ALT both <3 x ULN; ALP <2.5 x ULN; For patients with Gilbert's syndrome, total bilirubin ≤3x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07085572 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy, allogeneic stem cell transplantation, autologous stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify